Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
From TechCrunch
By Anna Heim
July 5, 2024
Welcome to Startups Weekly — TechCrunch’s weekly recap of everything you can’t miss from the world of startups. Sign up here to get it in your inbox every Friday.
Even seemingly crowded categories can see newcomers climb up the ranks. This includes social media: A new app called noplace hit No. 1 on the App Store right as it launched out of invite-only mode.
Besides confirming user appetite for new forms of social media, this also goes to show that it is still possible to go viral in 2024, as did French app ten ten earlier this year. Both apps also show that there’s value in revisiting older tech ideas — Myspace for nospace and walkie-talkies for ten ten.
It is also a reminder that consumer tech can find VC backers. It is a segment noplace CEO Tiffany Zhong knows well; before starting this company and raising funding from investors, including Alexis Ohanian’s 776 and Forerunner Ventures, she helped Binary Capital source early-stage consumer deals before creating early-stage consumer fund Pineapple Capital.
One area of tech that’s particularly hopeful is startups fighting cancer — and getting venture funding to do so. Biotech startup Granza Bio is one of these and raised a $7 million seed from Felicis, Refactor, and Y Combinator to advance delivery of cancer treatments.
Granza Bio is a winter 2024 Y Combinator grad, and YC wants to back more startups like it. YC’s request for startups (RFS) shared in February included a call for “a way to end cancer.” The main focus of that RFS was on startups that can reduce the cost of MRIs — not a perfect answer since MRIs are known to produce false positives. So it’s noteworthy that the accelerator is actually approaching the battle against cancer from multiple angles, including biotech.
Another interesting note: Felicis is a generalist VC firm but invests 10% to 15% of its capital into biology-focused startups. That’s also a sign that biotech is going mainstream and is another reason to keep an eye on new startups emerging in this space.
Evolve Bank’s data breach is sending waves through fintech, with several startups caught in the turmoil. Yieldstreet confirmed some of its customers were affected, as did Wise. Meanwhile, Fintech Business Weekly author Jason Mikula said he received a cease-and-desist letter from the bank, amid concerns that all the impacted fintechs may not yet have received details about what information was stolen in the breach.
Will Musk vs. Trump affect xAI’s $5 billion debt deal?
While the online feud between Elon Musk and President Donald Trump seemed to drive traffic to Musk’s social media platform X (formerly Twitter), it could also create issues for the platform’s parent company xAI.
Jun 7, 2025
Superblocks CEO: How to find a unicorn idea by studying AI system prompts
Brad Menezes, CEO of enterprise vibe coding startup Superblocks, is convinced that the next crop of billion-dollar startup ideas are hiding in almost plain sight: system prompts.
Jun 7, 2025
Meet the Finalists: VivaTech’s 5 Most Visionary Startups of 2025
Narrowing down the 30 most visionary startups of the year to just five finalists was no easy feat. VivaTech’s Innovation of the Year attracted an extraordinary pool of applicants—startups tackling massive global challenges with bold, technically sophisticated, and scalable solutions. From redefining human-machine interaction to revolutionizing healthcare, climate, and infrastructure, each company brought something unique […]
Jun 6, 2025